While producing half-antibodies for bispecific antibody therapeutics in E. coli has its advantages over a mammalian expression system, it also comes with challenges associated with soluble expression and effective folding of these complex proteins. The merits and challenges of using a microbial host for half-antibody production will be discussed, with a focus on a chaperone overexpression strategy to achieve high titers in a short amount of time. To develop a high titer E. coli process, we looked to the mammalian expression system to better understand the mechanisms involved in antibody folding. By overexpressing the endogenous E. coli protein FkpA, we can facilitate similar folding mechanisms, suggesting that FkpA could be acting as an ana...
Background: The overproduction of recombinant proteins in host cells often leads to their misfolding...
High expression of recombinant antibody fragments, such as single-chain variable fragments (scFvs), ...
Therapeutic protein production in yeast is a reality in industry with an untapped potential to expan...
In a systematic study of the periplasmic folding of antibody fragments in Escherichia coli, we have ...
In a systematic study of the periplasmic folding of antibody fragments in Escherichia coli, we have ...
In a systematic study of the periplasmic folding of antibody fragments in Escherichia coli, we have ...
Therapeutic protein production in yeast is a reality in industry with an untapped potential to expan...
Therapeutic protein production in yeast is a reality in industry with an untapped potential to expan...
Using recombinant antibodies functionally expressed by secretion to the periplasm in Escherichia col...
Therapeutic protein drugs are part of an emerging new generation of pharmaceutical products. However...
Using recombinant antibodies functionally expressed by secretion to the periplasm in Escherichia col...
Using recombinant antibodies functionally expressed by secretion to the periplasm in Escherichia col...
Using recombinant antibodies functionally expressed by secretion to the periplasm in Escherichia col...
AbstractImproper protein folding or aggregation can frequently be responsible for low expression and...
High expression of recombinant antibody fragments, such as single-chain variable fragments (scFvs), ...
Background: The overproduction of recombinant proteins in host cells often leads to their misfolding...
High expression of recombinant antibody fragments, such as single-chain variable fragments (scFvs), ...
Therapeutic protein production in yeast is a reality in industry with an untapped potential to expan...
In a systematic study of the periplasmic folding of antibody fragments in Escherichia coli, we have ...
In a systematic study of the periplasmic folding of antibody fragments in Escherichia coli, we have ...
In a systematic study of the periplasmic folding of antibody fragments in Escherichia coli, we have ...
Therapeutic protein production in yeast is a reality in industry with an untapped potential to expan...
Therapeutic protein production in yeast is a reality in industry with an untapped potential to expan...
Using recombinant antibodies functionally expressed by secretion to the periplasm in Escherichia col...
Therapeutic protein drugs are part of an emerging new generation of pharmaceutical products. However...
Using recombinant antibodies functionally expressed by secretion to the periplasm in Escherichia col...
Using recombinant antibodies functionally expressed by secretion to the periplasm in Escherichia col...
Using recombinant antibodies functionally expressed by secretion to the periplasm in Escherichia col...
AbstractImproper protein folding or aggregation can frequently be responsible for low expression and...
High expression of recombinant antibody fragments, such as single-chain variable fragments (scFvs), ...
Background: The overproduction of recombinant proteins in host cells often leads to their misfolding...
High expression of recombinant antibody fragments, such as single-chain variable fragments (scFvs), ...
Therapeutic protein production in yeast is a reality in industry with an untapped potential to expan...